List of Angiotensin-receptor blocker (ARB) trials for COVID-19:
- Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection. Intervention: Losartan 12.5mg bid, can be increased based on SBP.
- Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease. Intervention: Valsartan titrated based on BP, maximum of 160mg bid.
- COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED). Intervention: Losartan, not specified.
- Study of Open Label Losartan in COVID-19. Intervention: Losartan 20mg qd, escalated to 50mg od.
- Losartan for Patients With COVID-19 Requiring Hospitalization. Intervention: Losartan 50mg od.
- Losartan for Patients With COVID-19 Not Requiring Hospitalization. Intervention: Losartan 25mg od.
- Coronavirus Response - Active Support for Hospitalised Covid-19 Patients (CRASH-19). Intervention: Losartan 100mg od.
- Telmisartan for Treatment of COVID-19 Patients. Intervention: Telmisartan 80mg bid.
- Results: Preliminary results
- Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE). Intervention: Telmisartan 20mg od.
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY). Intervention: ARB, dose/medication not specified.
- Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia. Intervention: Losartan 25mg bid.
- Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN). Intervention: Losartan 50mg od.
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT). Intervention: Candesartan 4mg od, titrated up based on BP.
- Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients. Intervention: Telmisartan 40mg od.
- Host Response Mediators in Coronavirus (COVID-19) Infection (ARBS CORONA I). Intervention: observational study of existing ACEi/ARB users.
- Host response mediators in Coronavirus (COVID-19) infection - Is there a protective effect of ARBs on outcomes of Coronavirus infection? (ARBs CORONA II). Intervention: Losartan, dose/frequency not stated.
- The McGill RAAS-COVID-19 Randomized Controlled Trial (RAAS-COVID). Intervention: observational study of existing ACEi/ARB users. Will suspend or hold ACEi/ARB.
- Telmisartan in Respiratory Failure Due to COVID-19 (STAR-COVID). Intervention: Telmisartan 40mg od.
ACE inhibitor trials:
- Ramipril for the Treatment of COVID-19 (RAMIC). Intervention: Ramipril 2.5 od.
Other trials of renin-angiotensin modulation for COVID-19:
- Treatment of Angiotensin Peptide (1-7) for COVID-19
- Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)
- TXA COVID-19 Clinical Trial
- RAS and Coagulopathy in COVID19